The antiapoptotic protein, B-cell lymphoma 2 (BCL-2), is overexpressed in AML, specifically in leukemic stem cells (LSC), and its dysregulation is related to chemotherapy resistance and poor clinical outcomes [4,5,6,7]. Here, BCL2 is linked to acute myeloid leukemia.